Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	COVID-19: Daily Top 10 Papers

Tuberculosis

Free Subscription Articles published in Am J Respir Crit Care Med Retrieve available abstracts of 74 articles: HTML format

Single Articles

November 2021
1. BUNYASI EW, Middelkoop K, Koch A, Hoosen Z, et al
   Molecular Detection of Airborne Mycobacterium tuberculosis in South African High Schools.
   Am J Respir Crit Care Med. 2021 Nov 9. doi: 10.1164/rccm.202102-0405.
   PubMed     Abstract available
   
   
   
2. ADJOBIMEY M, Behr MA, Menzies D
   Individualized Treatment Duration in Tuberculosis Treatment: Precision versus Simplicity.
   Am J Respir Crit Care Med. 2021;204:1013-1014.
   PubMed    
   
   
   October 2021
3. ATRE SR, Jagtap JD, Faqih MI, Dumbare YK, et al
   Tuberculosis Pathways to Care and Transmission of Multidrug-Resistance in India.
   Am J Respir Crit Care Med. 2021 Oct 27. doi: 10.1164/rccm.202012-4333.
   PubMed     Abstract available
   
   
   
4. NOURSADEGHI M, Gupta RK
   New Insights into the Limitations of Host-Transcriptional Biomarkers of Tuberculosis.
   Am J Respir Crit Care Med. 2021 Oct 27. doi: 10.1164/rccm.202109-2146.
   PubMed    
   
   
   September 2021
5. MULENGA H, Musvosvi M, Mendelsohn SC, Penn-Nicholson A, et al
   Longitudinal Dynamics of a Blood Transcriptomic Signature of Tuberculosis.
   Am J Respir Crit Care Med. 2021 Sep 14. doi: 10.1164/rccm.202103-0548.
   PubMed     Abstract available
   
   
   
6. DARTOIS V, Dick T
   A Ginger Root or Plum Model for the Tuberculosis "Granuloma"?
   Am J Respir Crit Care Med. 2021;204:505-507.
   PubMed    
   
   
   August 2021
7. DAVIS JL, Checkley W
   Characterization of Air Pollution Exposures as Risk Factors for Tuberculosis Infection.
   Am J Respir Crit Care Med. 2021 Aug 30. doi: 10.1164/rccm.202107-1795.
   PubMed    
   
   
   
8. GAUSI K, Ignatius EH, Sun X, Kim S, et al
   A Semi-Mechanistic Model of the Bactericidal Activity of High-Dose Isoniazid Against Multi-Drug-Resistant Tuberculosis: Results from a Randomized Clinical Trial.
   Am J Respir Crit Care Med. 2021 Aug 17. doi: 10.1164/rccm.202103-0534.
   PubMed     Abstract available
   
   
   
9. MITNICK CD, Furin JJ, Hewison C
   The Reductionist Conundrum of an "Updated" Definition of Extensively Drug-resistant Tuberculosis.
   Am J Respir Crit Care Med. 2021 Aug 10. doi: 10.1164/rccm.202106-1516.
   PubMed    
   
   
   
10. VERMA R, Patil S, Zhang N, Moreira FMF, et al
    A Rapid Pharmacogenomic Assay to Detect NAT2 Polymorphisms and Guide Isoniazid Dosing for Tuberculosis Treatment.
    Am J Respir Crit Care Med. 2021 Aug 10. doi: 10.1164/rccm.202103-0564.
    PubMed     Abstract available
    
    
    
11. IMPERIAL MZ, Phillips PPJ, Nahid P, Savic RM, et al
    Precision-enhancing Risk Stratification Tools for Selecting Optimal Treatment Durations in Tuberculosis Clinical Trials.
    Am J Respir Crit Care Med. 2021 Aug 4. doi: 10.1164/rccm.202101-0117.
    PubMed     Abstract available
    
    
    
12. BLOUNT RJ, Phan H, Trinh T, Dang H, et al
    Indoor Air Pollution and Susceptibility to Tuberculosis Infection in Urban Vietnamese Children.
    Am J Respir Crit Care Med. 2021 Aug 3. doi: 10.1164/rccm.202101-0136.
    PubMed     Abstract available
    
    
    June 2021
13. ROELENS M, Battista Migliori G, Rozanova L, Estill J, et al
    Evidence-based Definition for Extensively Drug-resistant Tuberculosis.
    Am J Respir Crit Care Med. 2021 Jun 9. doi: 10.1164/rccm.202009-3527.
    PubMed     Abstract available
    
    
    May 2021
14. WELLS G, Glasgow JN, Nargan K, Lumamba K, et al
    microCT Analysis of the Human Tuberculous Lung Reveals Remarkable Heterogeneity in 3D Granuloma Morphology.
    Am J Respir Crit Care Med. 2021 May 20. doi: 10.1164/rccm.202101-0032.
    PubMed     Abstract available
    
    
    April 2021
15. 
    Retraction: Isoniazid and Rifapentine Treatment Eradicates Persistent Mycobacterium tuberculosis in Macaques.
    Am J Respir Crit Care Med. 2021;203:1045.
    PubMed    
    
    
    
16. HUDDART S, Savic RM, Cattamanchi A
    Is Glycemic Control the Secret to Tuberculosis Control?
    Am J Respir Crit Care Med. 2021 Apr 7. doi: 10.1164/rccm.202103-0703.
    PubMed    
    
    
    March 2021
17. BEHR MA, Kaufmann E, Duffin J, Edelstein PH, et al
    Latent Tuberculosis: Two Centuries of Confusion.
    Am J Respir Crit Care Med. 2021 Mar 24. doi: 10.1164/rccm.202011-4239.
    PubMed     Abstract available
    
    
    
18. LIU Q, You N, Pan H, Shen Y, et al
    Glycemic Trajectories After Tuberculosis Diagnosis and Treatment Outcomes of New Tuberculosis Patients: A Prospective Study in Eastern China.
    Am J Respir Crit Care Med. 2021 Mar 11. doi: 10.1164/rccm.202007-2634.
    PubMed     Abstract available
    
    
    
19. KENDALL EA, Shrestha S, Dowdy DW
    Reply to: Subclinical Tuberculosis: Some Flies in the Ointment.
    Am J Respir Crit Care Med. 2021 Mar 9. doi: 10.1164/rccm.202102-0367.
    PubMed    
    
    
    
20. PIERCE CW
    Subclinical Tuberculosis: Some Flies in the Ointment.
    Am J Respir Crit Care Med. 2021 Mar 9. doi: 10.1164/rccm.202101-0227.
    PubMed    
    
    
    
21. LE ROUX SP, Upton C, Vanker N, Dooley KE, et al
    Resistance-Conferring Mycobacterial Mutations and Quantification of Early Bactericidal Activity.
    Am J Respir Crit Care Med. 2021;203:635-637.
    PubMed    
    
    
    February 2021
22. ESCALANTE P, Wilson JW
    New Diagnostics to Infer Risk in Tuberculosis: Is the Term Latent Tuberculosis Infection Obsolete?
    Am J Respir Crit Care Med. 2021 Feb 17. doi: 10.1164/rccm.202101-0131.
    PubMed    
    
    
    January 2021
23. MPANDE CAM, Musvosvi M, Rozot V, Mosito B, et al
    Antigen-specific T Cell Activation Distinguishes Between Recent and Remote Tuberculosis Infection.
    Am J Respir Crit Care Med. 2021 Jan 6. doi: 10.1164/rccm.202007-2686.
    PubMed     Abstract available
    
    
    
24. FRANKE MF, Khan P, Hewison C, Khan U, et al
    Culture Conversion in Patients Treated with Bedaquiline and/or Delamanid. A Prospective Multicountry Study.
    Am J Respir Crit Care Med. 2021;203:111-119.
    PubMed     Abstract available
    
    
    December 2020
25. HOSODA C, Ishiguro T, Shimizu Y, Kanegane H, et al
    Mycobacterium genavense Infection Presenting as an Endobronchial Polyp and Upper Lobe Atelectasis.
    Am J Respir Crit Care Med. 2020;202:e144-e145.
    PubMed    
    
    
    November 2020
26. KENDALL EA, Shrestha S, Dowdy DW
    The Epidemiological Importance of Subclinical Tuberculosis: A Critical Re-Appraisal.
    Am J Respir Crit Care Med. 2020 Nov 16. doi: 10.1164/rccm.202006-2394.
    PubMed     Abstract available
    
    
    September 2020
27. 
    Erratum: Lower Bacillus Calmette-Guerin Protection against Mycobacterium tuberculosis Infection after Exposure to Beijing Strains.
    Am J Respir Crit Care Med. 2020;202:909-910.
    PubMed    
    
    
    
28. CHANG KC, Yew WW
    ATS/CDC/ERS/IDSA Clinical Practice Guidelines for Treatment of Drug-Resistant Tuberculosis: A Two-edged Sword?
    Am J Respir Crit Care Med. 2020;202:777-778.
    PubMed    
    
    
    
29. SOTGIU G, Battista Migliori G, Menzies D, Mase S, et al
    Reply to Chang and Yew.
    Am J Respir Crit Care Med. 2020;202:778-779.
    PubMed    
    
    
    August 2020
30. BURZYNSKI J, Keshavjee S
    Supporting a Comprehensive, International Approach to Global Tuberculosis Eradication is the Right Thing to Do.
    Am J Respir Crit Care Med. 2020 Aug 24. doi: 10.1164/rccm.202007-2976.
    PubMed    
    
    
    
31. O'DONNELL M, Mathema B
    Operational Research on the Treatment of Drug-resistant Tuberculosis: Exciting Results that Need to be Protected.
    Am J Respir Crit Care Med. 2020 Aug 21. doi: 10.1164/rccm.202007-2974.
    PubMed    
    
    
    
32. DAWRS SN, Kautz M, Chan ED, Honda JR, et al
    Mycobacterium abscessus and Gastroesophageal Reflux: An In Vitro Study.
    Am J Respir Crit Care Med. 2020;202:466-469.
    PubMed    
    
    
    July 2020
33. SCHLUGER NW
    Prevention of Multidrug-resistant Tuberculosis in Close Contacts: Back to the Future?
    Am J Respir Crit Care Med. 2020 Jul 27. doi: 10.1164/rccm.202006-2488.
    PubMed    
    
    
    
34. MENZIES NA, Bellerose M, Testa C, Swartwood N, et al
    Impact of Effective Global Tuberculosis Control on Health and Economic Outcomes in the United States.
    Am J Respir Crit Care Med. 2020 Jul 9. doi: 10.1164/rccm.202003-0526.
    PubMed     Abstract available
    
    
    
35. PODANY AT
    Simplifying Rifapentine Dosing for Tuberculosis Treatment and Prevention.
    Am J Respir Crit Care Med. 2020 Jul 7. doi: 10.1164/rccm.202006-2144.
    PubMed    
    
    
    
36. CUTLER T, Scales D, Levine W, Schluger N, et al
    A Novel Viral Epidemic Collides with an Ancient Scourge: COVID-19 Associated with Tuberculosis.
    Am J Respir Crit Care Med. 2020 Jul 1. doi: 10.1164/rccm.202003-0828.
    PubMed    
    
    
    June 2020
37. RODRIGUEZ CA, Sy KTL, Mitnick CD, Franke MF, et al
    Time Dependent Confounding in Tuberculosis Treatment Outcome Analyses: A Review of a Source of Bias.
    Am J Respir Crit Care Med. 2020 Jun 18. doi: 10.1164/rccm.202001-0220.
    PubMed    
    
    
    
38. HUANG CC, Becerra MC, Calderon R, Contreras C, et al
    Isoniazid Preventive Therapy in Contacts of Multidrug-resistant Tuberculosis.
    Am J Respir Crit Care Med. 2020 Jun 17. doi: 10.1164/rccm.201908-1576.
    PubMed     Abstract available
    
    
    
39. 
    Erratum: Tuberculosis Diagnosis in Children Using Xpert Ultra on Different Respiratory Specimens.
    Am J Respir Crit Care Med. 2020;201:1454.
    PubMed    
    
    
    
40. JAIN S, Kumar P, Goyal JP
    Utility of Xpert Ultra on Different Respiratory Specimens in Children.
    Am J Respir Crit Care Med. 2020;201:1452.
    PubMed    
    
    
    
41. ZAR HJ
    Reply to Jain et al.: Utility of Xpert Ultra on Different Respiratory Specimens in Children.
    Am J Respir Crit Care Med. 2020;201:1452-1453.
    PubMed    
    
    
    May 2020
42. SCHEUERMANN L, Pei G, Domaszewska T, Zyla J, et al
    Platelets Restrict the Oxidative Burst in Phagocytes and Facilitate Primary Progressive Tuberculosis.
    Am J Respir Crit Care Med. 2020 May 18. doi: 10.1164/rccm.201910-2063.
    PubMed     Abstract available
    
    
    
43. HIBMA JE, Radtke KK, Dorman SE, Jindani A, et al
    Rifapentine Population Pharmacokinetics and Dosing Recommendations for Latent Tuberculosis Infection.
    Am J Respir Crit Care Med. 2020 May 15. doi: 10.1164/rccm.201912-2489.
    PubMed     Abstract available
    
    
    
44. DAVIDS M, Pooran A, Hermann C, Mottay L, et al
    A Human Lung Challenge Model to Evaluate the Safety and Immunogenicity of PPD and Live Bacillus Calmette-Guerin.
    Am J Respir Crit Care Med. 2020;201:1277-1291.
    PubMed     Abstract available
    
    
    April 2020
45. DHEDA K, Davids M
    Latent Tuberculosis Infection-associated Immunodiagnostic Test Responses as Biomarkers of Incipient Tuberculosis: Fruitful or Futile?
    Am J Respir Crit Care Med. 2020;201:895-898.
    PubMed    
    
    
    
46. STOUT JE, Turner NA, Belknap RW, Horsburgh CR, et al
    Reply to: Trials of Tuberculosis Preventive Therapy in People with HIV Infection.
    Am J Respir Crit Care Med. 2020 Apr 13. doi: 10.1164/rccm.202003-0855.
    PubMed    
    
    
    
47. SWINDELLS S, Hughes M, Chaisson RE
    Trials of Tuberculosis Preventive Therapy in People with HIV Infection.
    Am J Respir Crit Care Med. 2020 Apr 13. doi: 10.1164/rccm.202003-0761.
    PubMed    
    
    
    March 2020
48. DOOLEY KE, Miyahara S, von Groote-Bidlingmaier F, Sun X, et al
    Reply to: High-dose First-line Treatment Regimen for Recurrent Rifampicin-susceptible Tuberculosis.
    Am J Respir Crit Care Med. 2020 Mar 4. doi: 10.1164/rccm.202002-0359.
    PubMed    
    
    
    
49. DECROO T, de Jong BC, Piubello A, Souleymane MB, et al
    High-dose First-line Treatment Regimen for Recurrent Rifampicin-susceptible Tuberculosis.
    Am J Respir Crit Care Med. 2020 Mar 4. doi: 10.1164/rccm.202001-0201.
    PubMed    
    
    
    February 2020
50. WASSERMAN S, Furin J
    Clarity with INHindsight: High-Dose Isoniazid for Drug-Resistant Tuberculosis with inhA Mutations.
    Am J Respir Crit Care Med. 2020 Feb 20. doi: 10.1164/rccm.202002-0264.
    PubMed    
    
    
    
51. 
    Erratum: Treatment of Drug-Resistant Tuberculosis. An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline.
    Am J Respir Crit Care Med. 2020;201:500-501.
    PubMed    
    
    
    
52. VERNON A, Bishai W
    Modeling Treatment of Latent Tuberculosis: Shortening the Leap of Faith?
    Am J Respir Crit Care Med. 2020;201:405-406.
    PubMed    
    
    
    
53. ANDRES S, Merker M, Heyckendorf J, Kalsdorf B, et al
    Bedaquiline-resistant Tuberculosis: Dark Clouds on the Horizon.
    Am J Respir Crit Care Med. 2020 Feb 13. doi: 10.1164/rccm.201909-1819.
    PubMed    
    
    
    January 2020
54. DE JAGER VR, Vanker N, van der Merwe L, van Brakel E, et al
    Optimising beta-lactams Against Tuberculosis.
    Am J Respir Crit Care Med. 2020 Jan 10. doi: 10.1164/rccm.201911-2149.
    PubMed    
    
    
    
55. VERRALL AJ, Chaidir L, Ruesen C, Apriani L, et al
    Lower BCG Protection Against Mycobacterium tuberculosis Infection After Exposure to Beijing Strains.
    Am J Respir Crit Care Med. 2020 Jan 8. doi: 10.1164/rccm.201912-2349.
    PubMed    
    
    
    
56. MCSHANE H
    Controlled Human Infection Models - Is it Really Feasible to Give People Tuberculosis?
    Am J Respir Crit Care Med. 2020 Jan 6. doi: 10.1164/rccm.201912-2408.
    PubMed    
    
    
    December 2019
57. GUPTA RK, Lipman M, Jackson C, Sitch A, et al
    Quantitative Interferon Gamma Release Assay and Tuberculin Skin Test Results to Predict Incident Tuberculosis: A Prospective Cohort Study.
    Am J Respir Crit Care Med. 2019 Dec 11. doi: 10.1164/rccm.201905-0969.
    PubMed     Abstract available
    
    
    
58. ABUBAKAR I, Cobelens FG, Rangaka MX
    The Risk of Falsely Declaring Non-Inferiority of Novel Latent Tuberculosis Treatment in Large Trials.
    Am J Respir Crit Care Med. 2019 Dec 9. doi: 10.1164/rccm.201911-2258.
    PubMed    
    
    
    November 2019
59. NISHIZAWA S, Tobino K
    Asymptomatic Tuberculous Pleurisy Mimicking Mesothelioma.
    Am J Respir Crit Care Med. 2019 Nov 25. doi: 10.1164/rccm.201906-1223.
    PubMed    
    
    
    
60. NAHID P, Mase SR, Migliori GB, Sotgiu G, et al
    Treatment of Drug-Resistant Tuberculosis. An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline.
    Am J Respir Crit Care Med. 2019;200:e93-e142.
    PubMed     Abstract available
    
    
    
61. OH JY, Min KH, Lee SY, Shim JJ, et al
    Invasive Endobronchial Mycobacterium kansasii Infection.
    Am J Respir Crit Care Med. 2019;200:e143-e144.
    PubMed    
    
    
    
62. STOUT JE, Turner NA, Belknap RW, Horsburgh CR, et al
    Optimizing the Design of Latent Tuberculosis Treatment Trials: Insights from Mathematical Modeling.
    Am J Respir Crit Care Med. 2019 Nov 11. doi: 10.1164/rccm.201908-1606.
    PubMed     Abstract available
    
    
    
63. NARITA M, Sullivan Meissner J, Burzynski J
    Use of Modeling to Inform Tuberculosis Elimination Strategies.
    Am J Respir Crit Care Med. 2019 Nov 7. doi: 10.1164/rccm.201910-2061.
    PubMed    
    
    
    October 2019
64. TEZERA LB, Mansour S, Elkington P
    Reconsidering the Optimal Immune Response to Mycobacterium tuberculosis.
    Am J Respir Crit Care Med. 2019 Oct 28. doi: 10.1164/rccm.201908-1506.
    PubMed     Abstract available
    
    
    
65. FOREMAN TW, Bucsan AN, Mehra S, Peloquin C, et al
    Isoniazid and Rifapentine Treatment Eradicates Persistent Mycobacterium tuberculosis in Macaques.
    Am J Respir Crit Care Med. 2019 Oct 24. doi: 10.1164/rccm.201903-0646.
    PubMed     Abstract available
    
    
    
66. MENZIES NA, Parriott A, Shrestha S, Dowdy DW, et al
    Comparative Modelling of Tuberculosis Epidemiology and Policy Outcomes in California.
    Am J Respir Crit Care Med. 2019 Oct 18. doi: 10.1164/rccm.201907-1289.
    PubMed     Abstract available
    
    
    
67. AUBRY A, Veziris N
    Smear Microscopy Complements Xpert MTB/RIF When Considering Nontuberculous Mycobacterial Infections.
    Am J Respir Crit Care Med. 2019;200:1072-1073.
    PubMed    
    
    
    
68. CHOI HW, Shin JH, Kee SJ, Kwon YS, et al
    Reply to Aubry and Veziris: Smear Microscopy Complements Xpert MTB/RIF When Considering Nontuberculous Mycobacterial Infections.
    Am J Respir Crit Care Med. 2019;200:1073-1074.
    PubMed    
    
    
    September 2019
69. SAGAR AS, Dodge DL, Salahuddin M, Warner MT, et al
    Pleural Diseases: Pleurodesis via Indwelling Pleural Catheter, Dasatinib-induced Pleural Effusion, and IL-27 in Tuberculosis Pleural Effusion.
    Am J Respir Crit Care Med. 2019;200:771-773.
    PubMed    
    
    
    March 2019
70. LEE HS, Kee SJ, Shin JH, Kwon YS, et al
    Xpert MTB/RIF Assay as a Substitute for Smear Microscopy in an Intermediate-Burden Setting.
    Am J Respir Crit Care Med. 2019;199:784-794.
    PubMed     Abstract available
    
    
    
71. YOON C, Semitala FC, Cattamanchi A
    Reply to Parker: Implications of Tuberculosis Sputum Culture Test Sensitivity on Accuracy of Other Diagnostic Modalities.
    Am J Respir Crit Care Med. 2019;199:665.
    PubMed    
    
    
    
72. PARKER RA
    Implications of Tuberculosis Sputum Culture Test Sensitivity on Accuracy of Other Diagnostic Modalities.
    Am J Respir Crit Care Med. 2019;199:664.
    PubMed    
    
    
    February 2019
73. GUPTA S, Krug S, Pokkali S, Leanderson T, et al
    Pharmacologic Exhaustion of Suppressor Cells with Tasquinimod Enhances Bacterial Clearance during Tuberculosis.
    Am J Respir Crit Care Med. 2019;199:386-389.
    PubMed    
    
    
    January 2019
74. SULIMAN S, Luabeya AKK, Geldenhuys H, Tameris M, et al
    Dose Optimization of H56:IC31 Vaccine for Tuberculosis-Endemic Populations. A Double-Blind, Placebo-controlled, Dose-Selection Trial.
    Am J Respir Crit Care Med. 2019;199:220-231.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Tuberculosis is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: